Background: Paclitaxel is an effective chemotherapeutic agent widely used for the treatment
of solid tumors. The major dose-limiting toxicity of paclitaxel is peripheral neuropathy. The …

The use of paclitaxel (Taxol), a microtubule stabilizer, for cancer treatment is often limited by
its associated peripheral neuropathy (chemotherapy-induced peripheral neuropathy [CIPN]) …

Painful peripheral neuropathy is the most dose-limiting side effect of paclitaxel (PTX), a
widely used anti-cancer drug to treat solid tumours. The understanding of the mechanisms …

The antineoplastic paclitaxel induces a sensory neuropathy that involves the spinal release
of neuroinflammatory mediators and activation of glial cells. Although the chemokine CCL2 …

Activation of innate immune mechanisms within the dorsal root ganglion and spinal dorsal
horn has been shown to play a key role in the development of neuropathic pain including …

Background Chemotherapy‐induced peripheral neuropathic pain (CIPNP) is a serious dose‐
limiting neurotoxic effect of cancer drug treatment. The underlying mechanism (s) of this …

Background Paclitaxel is an antimitotic antitumour drug highly effective against a broad
range of cancers considered refractory to conventional chemotherapy. One of the main …

Painful peripheral neuropathy is a serious dose-limiting side effect of paclitaxel therapy,
which unfortunately often happens during the optimal clinical management of chemotherapy …

Chemotherapy-induced peripheral neuropathy (CIPN) is a type of neuropathic pain that
represents a frequent and serious consequence of chemotherapy agents. Over the last …

Paclitaxel chemotherapy treatment often leads to neuropathic pain resistant to available
analgesic treatments. Recently spinal Toll-like receptor 4 (TLR4) and the transient receptor …